Overview

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Status:
Completed
Trial end date:
2020-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Momenta Pharmaceuticals, Inc.